Adam Crystal insider trades: Tango Therapeutics (TNGX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Adam reports to the SEC
Open-market buys and sales
20 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | TNGX | ↓ Sell | 5,000 | $22.42 | $112K | Direct | Nov 4, 2026 (2d) |
| Oct 1, 2026 | TNGX | ↓ Sell | 27,000 | $24.47 | $661K | Direct | Oct 5, 2026 (4d) |
| Sep 1, 2026 | TNGX | ↓ Sell | 27,000 | $22.37 | $604K | Direct | Sep 3, 2026 (2d) |
| Aug 3, 2026 | TNGX | ↓ Sell | 27,000 | $27.24 | $736K | Direct | Aug 5, 2026 (2d) |
| Jul 1, 2026 | TNGX | ↓ Sell | 27,000 | $29.59 | $799K | Direct | Jul 2, 2026 (1d) |
| Jun 1, 2026 | TNGX | ↓ Sell | 27,000 | $22.87 | $618K | Direct | Jun 3, 2026 (2d) |
| May 1, 2026 | TNGX | ↓ Sell | 27,000 | $21.23 | $573K | Direct | May 5, 2026 (4d) |
| Apr 15, 2026 | TNGX | ↓ Sell | 38,460 | $25.00 | $962K | Direct | Apr 16, 2026 (1d) |
| Apr 1, 2026 | TNGX | ↓ Sell | 27,000 | $21.20 | $572K | Direct | Apr 2, 2026 (1d) |
| Mar 5, 2026 | TNGX | ↓ Sell | 20,251 | $15.00 | $304K | Direct | Mar 9, 2026 (4d) |
| Feb 25, 2026 | TNGX | ↓ Sell | 54,345 | $12.77 | $694K | Direct | Feb 27, 2026 (2d) |
| Feb 3, 2026 | TNGX | ↓ Sell | 18,452 | $12.26 | $226K | Direct | Feb 4, 2026 (1d) |
| Feb 5, 2025 | TNGX | ↓ Sell | 14,283 | $3.07 | $44K | Direct | Feb 6, 2025 (1d) |
| Feb 7, 2024 | TNGX | ↓ Sell | 8,371 | $12.59 | $105K | Direct | Feb 8, 2024 (1d) |
| Nov 1, 2023 | TNGX | ↓ Sell | 7,507 | $8.39 | $63K | Direct | Nov 2, 2023 (1d) |
| Jan 4, 2022 | CCCC | ↓ Sell | 15,000 | $31.66 | $475K | Direct | Jan 5, 2022 (1d) |
| Oct 1, 2021 | CCCC | ↓ Sell | 15,000 | $45.43 | $681K | Direct | Oct 5, 2021 (4d) |
| Jul 29, 2021 | CCCC | ↓ Sell | 15,000 | $45.00 | $675K | Direct | Aug 2, 2021 (4d) |
| Jul 1, 2021 | CCCC | ↓ Sell | 15,000 | $37.98 | $570K | Direct | Jul 6, 2021 (5d) |
| Apr 5, 2021 | CCCC | ↓ Sell | 15,000 | $37.77 | $567K | Direct | Apr 6, 2021 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other TNGX insiders
Open-market trades in the last 12 months
About Adam Crystal's insider trades
Adam Crystal is President, R&D at Tango Therapeutics (TNGX). Since Apr 5, 2021, Adam has reported no open-market purchases and 20 sales worth $10.0M on SEC Form 4. In the last 12 months: 12 sales ($6.9M).
Their filings also include option exercises (18 filings), grants and awards (6 filings), shares withheld for taxes (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TNGX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.